Group 1 - BrainsWay Ltd. will report its fourth quarter and full year 2024 financial results on March 11, 2025, before the U.S. financial markets open [1] - A conference call and webcast will be held at 8:30 AM Eastern Time to discuss the results and provide an update on business operations [1][2] - BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) technology [3] Group 2 - The company has obtained three FDA-cleared indications for its TMS technology, which include major depressive disorder, obsessive-compulsive disorder, and smoking addiction [3] - BrainsWay is committed to advancing neuroscience and increasing global awareness and access to Deep TMS [3] - Additional clinical trials for Deep TMS are currently underway in various psychiatric, neurological, and addiction disorders [3]
BrainsWay to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025